1:00 pm – 1:03 pm: A Multicenter, Observational Study to Evaluate Corneal Neurosensory Abnormalities in Patients with Sjögren’s Dry Eye. Scott Hauswirth, OD, FAAO

1:03 pm – 1:06 pm: Outcome Measures and Metrics Used and Clinical Results of Trials for Sjögren’s versus Non-Sjögren’s Dry Eye. Kyle Munar, BA

1:06 pm – 1:09 pm: Minimally Invasive Glaucoma Surgery (MIGS) Outcomes in Uveitis: A Retrospective Single-Center Study. Elisah Huynh, BS

1:09 pm – 1:12 pm: Uveitic Glaucoma Interest Group Recommendations for Uveitis-Related Ocular Hypertension and Glaucoma Management. David S. Chu, MD

1:12 pm – 1:15 pm: Resolution of Refractory Bilateral Exudative Retinal Detachments with Teprotumumab in a Patient with Thyroid Eye Disease and Posterior Scleritis. Dylann K. Fujimoto, MD

1:15 pm – 1:18 pm: Prospective Validation of Serial Aqueous Humor Sampling for Longitudinal Ocular Proteomics: Safety Results from the OPTICA Trial in Geographic Atrophy. Tsai-Chu Yeh, MD, MTM

1:18 pm – 1:21 pm: The Gene Therapy Blind Spot: Video-Based Volumetric Analysis (V3xV) for Precision Subretinal Dosing. David RP Almeida, MD, MBA, PhD

1:21 pm – 1:24 pm: OCTA Imaging of Hyalocytes in Patients with Uveitis. Deep Parikh, MD and James Samson, MD

1:24 pm – 1:27 pm: Long-Term Follow-Up of Patients with Persistent Anterior Uveitis After Uncomplicated Cataract Surgery. Elyssa Dionne, BA

1:27 pm – 1:30 pm: Use of Immunomodulatory Treatment for Herpes Virus-Associated Ocular Inflammations. Parvin Aghayeva, MD

1:30 pm – 1:33 pm: Dropless Cataract Surgery in Patients with Inflammatory Eye Disease. Symon Ma, MS4

1:33 pm – 1:36 pm: Retinal Vasculitis in Intermediate Uveitis: A Hidden Driver of Uveitis Flares. Andrew Briere, DO

1:36 pm – 1:39 pm: Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): LUNA Trial 2-Year Results. Diana V. Do, MD and Roger A. Goldberg, MD

1:39 pm – 1:42 pm: Case of Bilateral Hyphema in a Patient Treated with Lutetium-177 (177Lu) Vipivotide Tetraxetan (Pluvicto) for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Roger Henry, MD

Panel Discussion 1:42 pm – 1:50 pm